Brought to you by 
Dura's Spiros inhaler to delivery Lilly insulin
13 Jul 1999
Executive Summary
Dura Pharmaceuticals (drug delivery and respiratory products) and Eli Lilly (major player in diabetes) will collaborate to develop a pulmonary delivery method for insulin.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dura's Spiros inhaler to delivery Lilly insulin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice